Form D · Biotechnology
MethylGene Inc.
Montreal, A8 · CIK 0001516722
Offering snapshot reported Nov 21, 2012 · SEC filing
- Reported sold
- $26.1M Offering amount: $35.5M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 9, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 21, 2012 | Initial | $26,125,730 | No comparison | 17 | SEC filing |
| Nov 16, 2012 | Amendment | $35,556,560 | $0vs Sep 11, 2012 | 20 | SEC filing |
| Sep 11, 2012 | Amendment | $35,556,560 | $43,419vs Apr 7, 2011 | 20 | SEC filing |
| Apr 7, 2011 | Initial | $35,513,141 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $1M
- Finders' fees
- $0
- Form D file number
- 021-187365
The $9,404,684 amount represents the aggregate exercise price of common share purchase warrants sold in the offering. All amounts stated in U.S. dollars based on an exchange rate of US$1.00 = CDN$0.9973 on November 20, 2012.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| MTS SECURITIES, LLC | 104059 | |
| Jefferies & Company, Inc. | 2347 |
Source: Form D, filed Nov 21, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andre Archimbaud | Director |
| Charles Baum | Director, Executive |
| Jeffrey M. Besterman | Executive |
| David J. Drutz | Director |
| Henry J. Fuchs | Director |
| Martin Godbout | Director, Executive |
| Charles Grubsztajn | Director, Executive |
| Rachel Humphrey | Executive |
| Klaus B. Kepper | Executive |
| Louis Lacasse | Director |
| Rodney W. Lappe | Director |
| Colin R. Mallet | Director |
| Jay Moorin | Director |
| Peggy Mulligan | Director |
| Gregory Reid | Executive |
| Peter Thompson | Director |
| Arkadil Vaisburg | Executive |
| Arkadii Vaisburg | Executive |
| Joseph Walewicz | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7150 Frederick Banting Street Suite 200
Montreal, A8, H4S 2A1
Montreal, A8, H4S 2A1